B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis

Although the primary endpoint, the change in the Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at week 12, did not reach statistical significance, patients treated with nipocalimab showed numerically greater improvements in disease activity scores, joint counts, and patient-reported outcomes compared with placebo.

also in 111,027 other papers